About Brekiya autoinjector
Brekiya—the first and only DHE autoinjector1,2
Provides patients the same powerful medication used in hospitals, in a disposable, ready-to-use, single-dose autoinjector1,3
1 of only 4 FDA-approved products indicated for cluster headache2
DHE=dihydroergotamine.
Brekiya autoinjector is bioequivalent to a subcutaneous D.H.E. 45® injection4*
MEAN PLASMA CONCENTRATION
SC=subcutaneous.
*Bioequivalence demonstrated in a randomized, open-label, crossover bioavailability study in 27 healthy, fasting adults. Brekiya autoinjector was well tolerated, with no serious adverse events reported.4
Brekiya autoinjector achieves peak concentration levels in a mean time of only 22 minutes4
A subcutaneous administration route offers a high bioavailability along with a prompt Tmax4,7
†Based on a study of D.H.E. 45®, not Brekiya autoinjector. Published literature reports that subcutaneous DHE demonstrates approximately 100% absolute bioavailability.7
It’s going to increase our toolbox and our opportunities for helping patients.
-DR. STEWART TEPPER
Brekiya autoinjector is ready at any point during an attack
Single-dose, prefilled, disposable device that provides patients with the same powerful medication used in hospitals1,3
May reduce headache recurrence8,9
May be helpful for patients who respond inadequately to oral therapies due to nausea/vomiting, gastroparesis, or delayed dosing3,10
No need for refrigeration, assembly, or priming the device1
Brekiya autoinjector is ready-to-use, with no need for refrigeration, assembly, or priming the device1
DOSING INFORMATION1
- Recommended dosage is 1 mg administered subcutaneously as a single 1 mL autoinjector into the thigh
- The dose can be repeated, as needed, at 1-hour intervals to a total dose of 3 mg (3 doses of 1 mg) subcutaneous delivery in a 24-hour period
- Total weekly dosage should not exceed 6 mg
- Brekiya autoinjector should not be used for chronic daily administration
For illustration purposes only. Not actual size. Brekiya autoinjector uses a 27-gauge needle.2
Watch a step-by-step video on how to use Brekiya autoinjector safely and confidently.
When following instructions for use, 100% of patients successfully self-administered a dose with Brekiya autoinjector11‡
‡Based on a human factor study of 30 untrained participants diagnosed with migraine and/or cluster headache.11
NEXT PAGE >
Expand
Collapse
WARNING: PERIPHERAL ISCHEMIA FOLLOWING COADMINISTRATION WITH STRONG CYP3A4 INHIBITORS
Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of dihydroergotamine with strong CYP3A4 inhibitors including protease inhibitors and macrolide antibiotics. Because CYP3A4 inhibition elevates the serum levels of dihydroergotamine, the risk for vasospasm leading to cerebral ischemia and/or ischemia of the extremities is increased. Hence, concomitant use of Brekiya with strong CYP3A4 inhibitors is contraindicated.
Brekiya is an ergotamine derivative indicated for the acute treatment of migraine with or without aura and the acute treatment of cluster headaches in adults.
Limitations of Use:
Brekiya is not indicated for the preventive treatment of migraine or for the management of hemiplegic migraine or migraine with brainstem aura.
- Concomitant use of strong CYP3A4 inhibitors
- Ischemic heart disease or coronary artery vasospasm
- Uncontrolled hypertension, peripheral arterial diseases, sepsis, following vascular surgery, or severe hepatic or renal impairment
- Concomitant use of other 5-HT1 agonists or ergotamine-containing or ergot-type medications within 24 hours
- Hypersensitivity to dihydroergotamine, ergot alkaloids, latex, or any of the ingredients in Brekiya
- Concomitant use with peripheral and central vasoconstrictors
- Myocardial Ischemia and/or Infarction, Other Cardiac Adverse Reactions, and Fatalities: In patients with risk factors predictive of coronary artery disease, consider first dose administration under medical supervision with an electrocardiogram.
- Cerebrovascular Adverse Reactions and Fatalities: Cerebrovascular hemorrhage, subarachnoid hemorrhage, and stroke have been reported; discontinue Brekiya if suspected.
- Other Vasospasm Related Adverse Reactions: Brekiya may cause vasospasm or elevation in blood pressure. Discontinue if signs or symptoms of vasoconstriction develop.
- Medication Overuse Headache: Detoxification may be necessary.
- Preterm Labor: Advise pregnant women of the risk.
- Fibrotic Complications: Pleural and retroperitoneal fibrosis have been reported following prolonged daily use of dihydroergotamine mesylate. Do not exceed the Brekiya dosing guidelines or use for chronic daily administration.
Serious cardiac events (including fatal) that have been reported with dihydroergotamine mesylate injection use include coronary artery vasospasm, transient myocardial ischemia, myocardial infarction, ventricular tachycardia, ventricular fibrillation.
- For subcutaneous injection only.
- Recommended dosage is 1 mg administered subcutaneously as a single 1 mL autoinjector.
- Do not exceed 3 mg (3 doses) in a 24-hour period.
- Do not exceed 6 mg (6 doses) in a week.
- Prior to initiation, a cardiovascular evaluation is recommended.
- Beta Blockers/Nicotine: May potentiate/provoke vasoconstriction.
- Selective Serotonin Reuptake Inhibitors: Weakness, hyperreflexia, and incoordination may occur with coadministration.
- Pregnancy: Based on animal data, may cause fetal harm.
- Lactation: Advise not to use during breastfeeding and for 3 days after the last dose.
To report SUSPECTED ADVERSE REACTIONS, contact Amneal Global Patient Safety at 1-877-835-5472 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Please see the Brekiya Full Prescribing Information, including Boxed Warning and Medication Guide.
